Built by former payers, HTA reviewers, and Industry Experts. market access risk assessment
Built by former payers, HTA reviewers, and Industry Experts. market access risk assessment
MARA Rating provides the pharmaceutical and investment community with the equivalent of a credit rating for medicines: an independent, forward-looking view of reimbursement probability. Our services are designed to support you at every stage — from early development through launch, deal-making, and long-term monitoring.
A snapshot of how your asset might score under current evidence.
Get an early, unpublished snapshot of how your asset might score under current evidence.
Use it in Phase II/III to test value narratives, comparators, or pricing ranges before launch.
A confidential rating that gives boards, deal teams, and investors clarity without public disclosure.
Supports portfolio prioritization, M&A diligence, and internal strategic planning.
A published MARA Rating that signals strong reimbursement prospects to external stakeholders.
Ideal for boosting confidence with partners, payers, and investors in licensing or fundraising discussions.
A one-time “what-if” analysis to explore how different pricing, trial, or policy choices could alter access prospects.
Rapid insights that help your team understand the impact of strategic decisions.
Single or multi-asset assessment that benchmarks an entire pipeline or investment portfolio.
An optional add-on that evaluates affordability, fairness, and ESG alignment.
Demonstrates commitment to equitable access — increasingly valued by HTA bodies and socially responsible investors.
Continuous monitoring of your rated asset.
Ratings are upgraded, downgraded, or placed under review as new evidence, HTA rulings, or policy changes emerge.
Keeps your valuation and negotiations anchored in the latest payer evidence.
A multi-asset assessment that benchmarks an entire pipeline or investment portfolio.
Highlights hidden risks, overlooked upsides, and helps allocate capital more effectively.
Reserved for HTA agencies, NGOs, and educational institutions.
We offer bespoke collaboration terms, including complimentary or discounted access to MARA Deep-Dive Reports and data sets. Contact us at sales@mararating.com to discuss your project and eligibility.
Prices in USD plus VAT. Complimentary summaries are for informational purposes only. The MARA Rating® is an independent opinion of a drug’s market-access risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. All opinions, analyses, and recommendations are statements of opinion, not statements of fact, and are supplied “as-is” without warranty of any kind, express or implied, including accuracy, completeness, or fitness for any particular purpose. Users assume full responsibility for their decisions and any consequences thereof. MARA expressly disclaims all liability for any outcomes arising from the use of, or actions taken based on, these reports.
© 2025 MARA Rating Company. All rights reserved.